Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Core Insights - Aura Biosciences is making significant progress in its clinical trials, particularly the Phase 3 CoMpass trial for early choroidal melanoma, with enrollment expected to complete by mid-2026 and topline data anticipated in the second half of 2027 [2][3] - The company is also advancing its Phase 1b/2 trial for non-muscle invasive bladder cancer (NMIBC), with initial three-month clinical data expected in mid-2026 [2][6] - A new formulation has achieved 12-month stability, which is aimed at expanding treatment opportunities in non-ocular solid tumors, starting with urologic oncology [2][8] Clinical Trials and Pipeline Developments - The ongoing Phase 3 CoMpass trial is the first registration-enabling study for early choroidal melanoma, evaluating bel-sar against a sham control [3][5] - The trial is designed to enroll patients with documented tumor growth, and the company is utilizing a patient identification tool to address the unmet need for vision-preserving therapies [4][5] - The Phase 1b/2 trial for NMIBC is evaluating two approaches: immune ablative and neoadjuvant designs, with monitoring for response assessments and safety [6][7] Financial Performance - As of December 31, 2025, the company reported cash and cash equivalents and marketable securities totaling $144.2 million, sufficient to fund operations into the first quarter of 2027 [17] - Research and development expenses for the full year 2025 were $90.3 million, an increase from $73.3 million in 2024, primarily due to ongoing clinical trial costs [17][21] - The net loss for the full year 2025 was $106.2 million, compared to $86.9 million in 2024, reflecting increased operational costs [17][22] Market Opportunities - Bel-sar has received Orphan Drug Designation and Fast Track designation from the FDA for early choroidal melanoma, indicating its potential as a first-line therapy [5] - The indication for metastases to the choroid has an estimated annual incidence of approximately 20,000 patients in the U.S. and Europe, highlighting a significant market opportunity [11] - The company is also initiating a Phase 1 trial for cancers of the ocular surface, which currently have no approved therapies, affecting around 35,000 patients annually in the U.S. and Europe [12][13]